Lexaria Bioscience Corp. LEXX
3.28
(0.09)
(2.67%)
as of 25 Sep
- Market cap
- $7.1M
- P/E
- 0.0×
Follow LEXX
Growth Flags
show if company had growth for consecutive years
| Older periods | Aug '25 | Nov '25 | Feb '26 | May '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(231.96%) | (155.10%) | (146.94%) | (162.60%) | |
| (182.50%) | (136.24%) | (125.68%) | (134.20%) | ||
ROIC |
(1,168.81%) | (6,795.20%) | (628.69%) | (662.56%) | |
Return on Tangible Assets |
(540.28%) | (261.80%) | (164.35%) | (197.72%) | |
Average Days of Receivables |
190.49 | 0.00 | 28.28 | 0.00 | |
Free Cash Flow per Share |
(8.79) | (6.15) | (5.81) | (4.55) | |
Free Cash Flow |
(10.55) | (8.78) | (9.47) | (7.53) | |
Capital Expenditures |
(0.10) | (0.07) | (0.09) | (0.10) | |
Piotroski F-Score |
3.00 | — | 2.00 | — | |
| Other line items | |||||
Cash ROIC |
(228.66%) | (97.32%) | (81.66%) | (93.27%) | |
Accounts Receivable Turnover |
2.70 | 0.00 | 2.90 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1,167.12% | 0.00% | 1,060.20% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
615.55% | 0.00% | 753.91% | 0.00% | |
Share Based Compensation of Revenue |
121.76% | 0.00% | 137.03% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.88 | 0.81 | 0.98 | 0.96 | |
Depreciation/Fixed assets |
0.38 | 0.33 | 0.36 | 0.33 | |
Capex/Depreciation |
(1.14) | (0.94) | (1.08) | (1.33) | |
Revenue per Share |
0.59 | 0.00 | 0.33 | 0.00 | |
Operating CF per Share |
(8.70) | (6.11) | (5.75) | (4.49) | |
Capex per Share |
(0.08) | (0.05) | (0.06) | (0.06) | |
Capex to Sales |
0.14 | 0.00 | 0.18 | 0.00 | |
Net Profit Margin |
(1,686.05%) | 0.00% | (1,758.28%) | 0.00% |
Columns are period end dates